Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.

ABSTRACT:

Introduction

A systematic literature review was conducted to review and summarize the economic impact of non-medical switching (NMS) from biologic originators to their biosimilars (i.e., switching a patient's medication for reasons irrelevant to the patient's health).

Methods

English publications reporting healthcare resource utilization (HRU) or costs associated with biosimilar NMS were searched in PubMed and EMBASE over the past 10 years and from selected scientific conferences over the past 3 years, along with gray literature for all biologics with an approved biosimilar (e.g., tumor-necrosis factor inhibitors, erythropoiesis-stimulating agents, insulin and hormone therapies).

Results

A total of 1311 publications were retrieved, where 54 studies met the selection c

SUBMITTER: Liu Y 

PROVIDER: S-EPMC6822838 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature